FDA panel backs stricter controls on Vicodin

The U.S. Food and Drug Administration may be set to reclassify hydrocodone-containing painkillers like Vicodin from Schedule III drugs to the more restrictive Schedule II, with an expert panel voting 19 to 10 in favor of the more stringent prescribing requirements. During a two-day hearing last week, the panel heard testimony from proponents who noted hydrocodone’s abuse potential (such products are currently the most-abused prescription medicine behind oxycodone), while critics argued that the move would hinder legitimate pain patients from obtaining treatment.

The FDA usually, but not always, follows the advice of its advisory panels.

The misuse of prescription painkillers was responsible for more than 475,000 emergency department visits in 2009, a number that nearly doubled in just five years, according to the Centers for Disease Control and Prevention.

About Erin Marie Daly

I’m a freelance journalist based in San Francisco. My book on prescription drug and heroin addiction was published in August 2014 by Counterpoint Press.
This entry was posted in Informational, Pharmaceutical Industry, Policy & Regulation and tagged , , , , , , , , , , , , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *